Filling the need for trusted information on national health issues

Since 2007, total spending on the EpiPen in Medicare Part D has grown substantially – doubling between 2014 and 2016


KFF analysis of a five percent sample of Medicare prescription drug event claims from the CMS Chronic Conditions Data Warehouse, 2007-2016.